Skip to main content

Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Sell if holding. Momentum 3.2/10 is below the 5.0 floor at $11.93 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 67.5): -1.5; Concentration risk — Customer: Cencora, McKesson, Cardinal Health, and CVS (71.0%).

Amneal Pharmaceuticals is a diversified biopharmaceutical company with three segments: Affordable Medicines (generics, injectables, biosimilars), Specialty (branded CNS/endocrine drugs including CREXONT and RYTARY), and AvKARE (government and institutional distribution). Revenue... Read more

$11.93+24.0% A.UpsideScore 5.4/10#16 of 29 Drug Manufacturers - Specialty & Generic
QualityF-score8 / 9FCF yield2.67%
Stop $11.52Target $14.79(analyst − 13%)A.R:R 3.5:1
Analyst target$17.00+42.5%5 analysts
$14.79our TP
$11.93price
$17.00mean
$19

Sell if holding. Momentum 3.2/10 is below the 5.0 floor at $11.93 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 67.5): -1.5; Concentration risk — Customer: Cencora, McKesson, Cardinal Health, and CVS (71.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.4/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Val8.0Qual5.9Grw3.5Mom3.2Sent6.4Ins5.1Peer3.3Tech8.4Risk4.05.4OVERALL

Recent Developments — Amneal Pharmaceuticals, Inc.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (3/4)
Attractive valuation
Risks
Concentration risk — Customer: Cencora, McKesson, Cardinal Health, and CVS (71.0%)
Leverage penalty (D/E 67.5): -1.5
Weak growth

Key Metrics

P/E (TTM)32.2
P/E (Fwd)10.1
Mkt Cap$3.8B
EV/EBITDA9.6
Profit Mgn4.0%
ROE—
Rev Growth3.9%
Beta1.32
DividendNone
Rating analysts11

Quality Signals

Piotroski F8/9

Concentration Risks(10-K Item 1A)

  • HIGHCustomerCencora, McKesson, Cardinal Health, and CVS71%
    10-K Item 1A: 'Our four largest customers, Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc. and CVS Health Corporation, accounted for approximately 71%, 70% and 70% of total net sales of products for the years ended December 31, 2025, 2024 and 2023, respectively.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Obv
1.0
Macd
1.4
Volume
2.1
Ma Position
4.0
Rsi
7.6
Uptrend pullback (RSI 39) - buy opportunityVolume distribution (falling OBV)Above 200-day MA

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
3.6
Growth Rank
4.4
Value Rank
5.3

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Revenue Growth
3.5
Low model confidence on this dimension (33%).
GatesMomentum 3.2<4.5A.R:R 3.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 79d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
39 · Neutral
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $11.88Resistance $13.92

Price Targets

$12
$15
A.Upside+24.0%
A.R:R3.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Momentum score 3.2/10 — below 4.5 minimum

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-08-04 (79d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is AMRX stock a buy right now?

Sell if holding. Momentum 3.2/10 is below the 5.0 floor at $11.93 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 67.5): -1.5; Concentration risk — Customer: Cencora, McKesson, Cardinal Health, and CVS (71.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $11.52. Score 5.4/10, moderate confidence.

What is the AMRX stock price target?

Take-profit target: $14.79 (+24.0% upside). Prior stop was $11.52. Stop-loss: $11.52.

What are the risks of investing in AMRX?

Concentration risk — Customer: Cencora, McKesson, Cardinal Health, and CVS (71.0%); Leverage penalty (D/E 67.5): -1.5; Weak growth.

Is AMRX overvalued or undervalued?

Amneal Pharmaceuticals, Inc. trades at a P/E of 32.2 (forward 10.1). TrendMatrix value score: 8.0/10. Verdict: Sell.

What do analysts say about AMRX?

11 analysts cover AMRX with a consensus score of 4.1/5. Average price target: $17.

What does Amneal Pharmaceuticals, Inc. do?Amneal Pharmaceuticals is a diversified biopharmaceutical company with three segments: Affordable Medicines (generics,...

Amneal Pharmaceuticals is a diversified biopharmaceutical company with three segments: Affordable Medicines (generics, injectables, biosimilars), Specialty (branded CNS/endocrine drugs including CREXONT and RYTARY), and AvKARE (government and institutional distribution). Revenue is highly concentrated through major pharmaceutical wholesalers in the U.S.

Related stocks: NBIX (Neurocrine Biosciences, Inc.) · ANIP (ANI Pharmaceuticals, Inc.) · INDV (Indivior Pharmaceuticals, Inc.) · COLL (Collegium Pharmaceutical, Inc.) · BCRX (BioCryst Pharmaceuticals, Inc.)